Daiichi Sankyo Korea and AstraZeneca Korea received approval for two additional Enhertu indications: 1L HER2-positive metastatic breast cancer and 2L HER2-positive metastatic gastric cancer

CAR-T Digest - August 2020

Weekly Digest - May 2026

07 May 2026: Daiichi Sankyo Korea and AstraZeneca Korea received approval for two additional Enhertu indications: 1L HER2-positive metastatic Breast cancer and 2L HER2-positive metastatic Gastric cancer

Enhertu has secured two major approvals in South Korea for first-line HER2-positive metastatic Breast cancer and second-line HER2-positive metastatic Gastric cancer
The Breast cancer approval was supported by results from the DESTINY-Breast09 trial, where Enhertu plus Pertuzumab reduced the risk of progression or death by 44% and achieved median progression-free survival of over 40.7 months versus the THP standard
In HER2-positive metastatic Gastric cancer, the DESTINY-Gastric04 trial showed that Enhertu reduced the risk of death by 30% compared with Ramucirumab plus Paclitaxel, while also improving overall survival and response rates
The expanded approvals address major unmet needs, as many HER2-positive breast cancer patients progress on existing frontline therapies and advanced gastric cancer continues to have limited HER2-targeted options beyond first-line treatment
Enhertu continues to strengthen its position as a leading HER2-targeted ADC across multiple tumor types and treatment settings, further advancing its role in the evolving HER2 oncology landscape